Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14381016 | 0.81 | LMNA (0.50) | LMNAKMT2ATSHRHTTSMN1; SMN2 | |
| SCHEMBL13035855 | 0.80 | LMNA (0.72) | LMNAKMT2ATSHRHTTSMN1; SMN2 | |
| SCHEMBL13034922 | 0.78 | LMNA (0.56) | LMNAKMT2ATSHRHTTSMN1; SMN2 | |
| SCHEMBL11912107 | 0.77 | HIF1A (0.47) | LMNAKMT2ATSHRHTTSMN1; SMN2 | |
| SCHEMBL2632344 | 0.76 | BCHE (0.46) | LMNAKMT2ATSHRHTTSMN1; SMN2 | |
| SCHEMBL15450758 | 0.76 | BCHE (0.47) | LMNATSHRSMN1; SMN2MAPTMAPK1 | |
| SCHEMBL13298385 | 0.75 | LMNA (0.53) | LMNAKMT2ATSHRHTTSMN1; SMN2 | |
| SCHEMBL14205323 | 0.74 | LMNA (0.49) | LMNAKMT2ATSHRMAPTMAPK1 | |
| SCHEMBL16351174 | 0.70 | SLC2A1 (0.46) | LMNATSHRHTTSMN1; SMN2BCHE | |
| SCHEMBL2519102 | 0.70 | THRA (0.52) | LMNAKMT2ATSHRHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353149-B2 | Compounds, compositions and methods for the treatment of diseases through inhibiting TGF-β activity | SOUTHERN RESEARCH INSTITUTE (US) | 2016-05-31 | — | — | US | disclosed |
| US-20140336115-A1 | Compounds, Compositions and Methods for the Treatment of Diseases Through Inhibiting TGF-ß Activity | SOUTHERN RESEARCH INSTITUTE (US) | 2014-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336115-A1 | Compounds, Compositions and Methods for the Treatment of Diseases Through Inhibiting TGF-ß Activity | TGFB1, TGFB2, TGFBR1 | LMNA 351/4885KMT2A 3485/4885TSHR 3314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.